What are bankers and analysts saying about concerns that an AI bubble could negatively impact credit markets? Read more here.
NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...
New specialty pharmacy and infusion suite combines compassionate nursing and infusion expertise for patients managing ...
Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...
The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the onset of migraines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results